// Psychiatry/Neurology (Expanded) - Drugs
// Auto-generated from modularize-data.js

const drugs = [

    {
        "id": "lithium-carbonate",
        "name": "Lithium Carbonate",
        "pharmacologicClass": "lithium",
        "therapeuticClass": "mood-stabilizers",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Inhibits inositol monophosphatase, affects neurotransmitter signaling.",
        "features": "Narrow therapeutic index, requires monitoring.",
        "clinicalChoice": "Bipolar disorder, acute mania.",
        "indications": [
            "Bipolar Disorder",
            "Acute Mania"
        ],
        "contraindications": [
            "Severe Renal Disease",
            "Severe Heart Disease"
        ],
        "sideEffects": [
            "Tremor",
            "Polyuria",
            "Thyroid dysfunction",
            "Nephrotoxicity"
        ],
        "interactions": "Thiazides, ACE inhibitors, NSAIDs increase lithium levels.",
        "interactionDetails": "THIAZIDES: MECHANISM - Thiazides cause volume depletion, increasing proximal tubule lithium reabsorption. CONSEQUENCE - Lithium toxicity with tremor, confusion, seizures. NSAIDS: MECHANISM - Reduce renal prostaglandins needed for lithium excretion. CONSEQUENCE - Increased lithium levels and toxicity.",
        "pageType": "drug"
    },
    {
        "id": "levodopa-carbidopa",
        "name": "Levodopa/Carbidopa",
        "pharmacologicClass": "dopamine-precursors",
        "therapeuticClass": "parkinson-disease-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Levodopa crosses blood-brain barrier, converted to dopamine.",
        "features": "Carbidopa prevents peripheral conversion.",
        "clinicalChoice": "First-line Parkinson treatment.",
        "indications": [
            "Parkinson Disease"
        ],
        "contraindications": [
            "MAOIs",
            "Angle-Closure Glaucoma"
        ],
        "sideEffects": [
            "Dyskinesias",
            "On-off phenomena",
            "Nausea",
            "Orthostatic hypotension"
        ],
        "interactions": "MAOIs, high-protein meals reduce absorption.",
        "interactionDetails": "MAOIS: MECHANISM - MAOIs prevent dopamine breakdown, while levodopa increases dopamine production. CONSEQUENCE - Risk of hypertensive crisis from excessive dopamine. Use MAO-B selective inhibitors only.",
        "pageType": "drug"
    },
    {
        "id": "pramipexole",
        "name": "Pramipexole",
        "pharmacologicClass": "dopamine-agonists",
        "therapeuticClass": "parkinson-disease-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Direct stimulation of dopamine receptors.",
        "features": "Non-ergot agonist, good for early PD.",
        "clinicalChoice": "Early Parkinson disease, restless leg syndrome.",
        "indications": [
            "Parkinson Disease",
            "Restless Leg Syndrome"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Impulse control disorders",
            "Sleep attacks",
            "Nausea"
        ],
        "interactions": "Antipsychotics antagonize effects.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "ropinirole",
        "name": "Ropinirole",
        "pharmacologicClass": "dopamine-agonists",
        "therapeuticClass": "parkinson-disease-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Direct stimulation of dopamine receptors.",
        "features": "Non-ergot agonist, impulse control risk.",
        "clinicalChoice": "Early PD, restless leg syndrome.",
        "indications": [
            "Parkinson Disease",
            "Restless Leg Syndrome"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Impulse control disorders",
            "Sleep attacks",
            "Nausea"
        ],
        "interactions": "Antipsychotics antagonize effects.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "selegiline",
        "name": "Selegiline",
        "pharmacologicClass": "mao-b-inhibitors",
        "therapeuticClass": "parkinson-disease-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Inhibit MAO-B enzyme, increase dopamine availability.",
        "features": "Irreversible MAO-B inhibitor.",
        "clinicalChoice": "Early PD, adjunct to levodopa.",
        "indications": [
            "Parkinson Disease"
        ],
        "contraindications": [
            "Meperidine Use"
        ],
        "sideEffects": [
            "Insomnia",
            "Nausea",
            "Dizziness"
        ],
        "interactions": "Meperidine, tramadol (serotonin syndrome).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "rasagiline",
        "name": "Rasagiline",
        "pharmacologicClass": "mao-b-inhibitors",
        "therapeuticClass": "parkinson-disease-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Inhibit MAO-B enzyme, increase dopamine availability.",
        "features": "Irreversible MAO-B inhibitor, neuroprotective.",
        "clinicalChoice": "Early or advanced PD.",
        "indications": [
            "Parkinson Disease"
        ],
        "contraindications": [
            "Severe Hepatic Impairment"
        ],
        "sideEffects": [
            "Insomnia",
            "Nausea",
            "Dizziness"
        ],
        "interactions": "Meperidine, tramadol (serotonin syndrome).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "phenobarbital",
        "name": "Phenobarbital",
        "pharmacologicClass": "gaba-enhancers",
        "therapeuticClass": "comprehensive-antiepileptics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Enhance GABA-mediated inhibition through various mechanisms.",
        "features": "GABA-A receptor enhancer, enzyme inducer.",
        "clinicalChoice": "Neonatal seizures, refractory epilepsy.",
        "indications": [
            "Neonatal Seizures",
            "Refractory Epilepsy"
        ],
        "contraindications": [
            "Porphyria",
            "Severe Respiratory Depression"
        ],
        "sideEffects": [
            "Sedation",
            "Weight gain",
            "Cognitive slowing"
        ],
        "interactions": "CNS depressants (additive sedation).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "gabapentin",
        "name": "Gabapentin",
        "pharmacologicClass": "gaba-enhancers",
        "therapeuticClass": "comprehensive-antiepileptics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Enhance GABA-mediated inhibition through various mechanisms.",
        "features": "Calcium channel modulator, renally excreted.",
        "clinicalChoice": "Partial seizures, neuropathic pain.",
        "indications": [
            "Partial Seizures",
            "Neuropathic Pain"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Sedation",
            "Weight gain",
            "Cognitive slowing"
        ],
        "interactions": "CNS depressants (additive sedation).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "fluoxetine",
        "name": "Fluoxetine",
        "pharmacologicClass": "selective-serotonin-reuptake-inhibitors-ssris",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Selectively inhibit serotonin reuptake, increasing synaptic serotonin.",
        "features": "First SSRI, long half-life (reduce discontinuation syndrome).",
        "clinicalChoice": "Depression, OCD, bulimia nervosa.",
        "indications": [
            "Depression",
            "OCD",
            "Bulimia Nervosa",
            "Panic Disorder"
        ],
        "contraindications": [
            "MAOIs",
            "Thioridazine Use"
        ],
        "sideEffects": [
            "Sexual dysfunction",
            "GI upset",
            "Insomnia",
            "Serotonin syndrome"
        ],
        "interactions": "MAOIs (serotonin syndrome), CYP2D6 inhibition.",
        "interactionDetails": "MAOIS: MECHANISM - Both increase synaptic serotonin through different pathways. CONSEQUENCE - Life-threatening serotonin syndrome with hyperthermia, rigidity, autonomic instability. Requires 2-week washout for most SSRIs, 5 weeks for fluoxetine.",
        "pageType": "drug"
    },
    {
        "id": "sertraline",
        "name": "Sertraline",
        "pharmacologicClass": "selective-serotonin-reuptake-inhibitors-ssris",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Selectively inhibit serotonin reuptake, increasing synaptic serotonin.",
        "features": "First-line for depression, safe post-MI.",
        "clinicalChoice": "Depression, post-MI, PTSD.",
        "indications": [
            "Depression",
            "PTSD",
            "Panic Disorder",
            "OCD"
        ],
        "contraindications": [
            "MAOIs",
            "Pimozide Use"
        ],
        "sideEffects": [
            "Sexual dysfunction",
            "GI upset",
            "Insomnia",
            "Serotonin syndrome"
        ],
        "interactions": "MAOIs (serotonin syndrome), CYP2D6 inhibition.",
        "interactionDetails": "MAOIS: MECHANISM - Both increase synaptic serotonin through different pathways. CONSEQUENCE - Life-threatening serotonin syndrome with hyperthermia, rigidity, autonomic instability. Requires 2-week washout for most SSRIs, 5 weeks for fluoxetine.",
        "pageType": "drug"
    },
    {
        "id": "escitalopram",
        "name": "Escitalopram",
        "pharmacologicClass": "selective-serotonin-reuptake-inhibitors-ssris",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Selectively inhibit serotonin reuptake, increasing synaptic serotonin.",
        "features": "Most selective SSRI, fewer drug interactions.",
        "clinicalChoice": "Generalized anxiety disorder, depression.",
        "indications": [
            "Depression",
            "Generalized Anxiety Disorder"
        ],
        "contraindications": [
            "MAOIs",
            "Pimozide Use"
        ],
        "sideEffects": [
            "Sexual dysfunction",
            "GI upset",
            "Insomnia",
            "Serotonin syndrome"
        ],
        "interactions": "MAOIs (serotonin syndrome), minimal CYP interactions.",
        "interactionDetails": "MAOIS: MECHANISM - Both increase synaptic serotonin through different pathways. CONSEQUENCE - Life-threatening serotonin syndrome with hyperthermia, rigidity, autonomic instability. Requires 2-week washout for most SSRIs, 5 weeks for fluoxetine.",
        "pageType": "drug"
    },
    {
        "id": "paroxetine",
        "name": "Paroxetine",
        "pharmacologicClass": "selective-serotonin-reuptake-inhibitors-ssris",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Selectively inhibit serotonin reuptake, increasing synaptic serotonin.",
        "features": "Strong anticholinergic effects, worst discontinuation syndrome.",
        "clinicalChoice": "Depression, anxiety disorders.",
        "indications": [
            "Depression",
            "Panic Disorder",
            "Social Anxiety Disorder"
        ],
        "contraindications": [
            "MAOIs",
            "Pregnancy"
        ],
        "sideEffects": [
            "Sexual dysfunction",
            "GI upset",
            "Insomnia",
            "Serotonin syndrome",
            "Weight gain",
            "Anticholinergic effects"
        ],
        "interactions": "MAOIs (serotonin syndrome), strong CYP2D6 inhibition.",
        "interactionDetails": "MAOIS: MECHANISM - Both increase synaptic serotonin through different pathways. CONSEQUENCE - Life-threatening serotonin syndrome with hyperthermia, rigidity, autonomic instability. Requires 2-week washout for most SSRIs, 5 weeks for fluoxetine.",
        "pageType": "drug"
    },
    {
        "id": "venlafaxine",
        "name": "Venlafaxine",
        "pharmacologicClass": "serotonin-norepinephrine-reuptake-inhibitors-snris",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Inhibit both serotonin and norepinephrine reuptake.",
        "features": "Dose-dependent: low dose (serotonin), high dose (serotonin + NE).",
        "clinicalChoice": "Depression, generalized anxiety disorder.",
        "indications": [
            "Depression",
            "Generalized Anxiety Disorder",
            "Social Anxiety Disorder"
        ],
        "contraindications": [
            "MAOIs",
            "Uncontrolled Hypertension"
        ],
        "sideEffects": [
            "Hypertension",
            "Sexual dysfunction",
            "Nausea",
            "Discontinuation syndrome"
        ],
        "interactions": "MAOIs (serotonin syndrome).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "duloxetine",
        "name": "Duloxetine",
        "pharmacologicClass": "serotonin-norepinephrine-reuptake-inhibitors-snris",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Inhibit both serotonin and norepinephrine reuptake.",
        "features": "Dual serotonin and norepinephrine reuptake inhibition.",
        "clinicalChoice": "Depression, diabetic neuropathy, fibromyalgia.",
        "indications": [
            "Depression",
            "Diabetic Neuropathy",
            "Fibromyalgia",
            "Chronic Musculoskeletal Pain"
        ],
        "contraindications": [
            "MAOIs",
            "Severe Liver Disease"
        ],
        "sideEffects": [
            "Hypertension",
            "Sexual dysfunction",
            "Nausea",
            "Discontinuation syndrome"
        ],
        "interactions": "MAOIs (serotonin syndrome).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "amitriptyline",
        "name": "Amitriptyline",
        "pharmacologicClass": "tricyclic-antidepressants-tcas",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block reuptake of serotonin and norepinephrine; also block histamine, muscarinic, and alpha receptors.",
        "features": "Tertiary amine TCA, strong anticholinergic and sedating.",
        "clinicalChoice": "Neuropathic pain, migraine prophylaxis, depression.",
        "indications": [
            "Depression",
            "Neuropathic Pain",
            "Migraine Prophylaxis"
        ],
        "contraindications": [
            "Recent MI",
            "MAOIs",
            "Arrhythmias"
        ],
        "sideEffects": [
            "Anticholinergic effects",
            "Sedation",
            "Orthostatic hypotension",
            "QT prolongation",
            "Seizures"
        ],
        "interactions": "MAOIs, QT-prolonging drugs.",
        "interactionDetails": "MAOIS: MECHANISM - Combined serotonin and norepinephrine effects. CONSEQUENCE - Risk of serotonin syndrome and hypertensive crisis. QT PROLONGATION: TCAs have quinidine-like effects, can cause fatal arrhythmias in overdose.",
        "pageType": "drug"
    },
    {
        "id": "nortriptyline",
        "name": "Nortriptyline",
        "pharmacologicClass": "tricyclic-antidepressants-tcas",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block reuptake of serotonin and norepinephrine; also block histamine, muscarinic, and alpha receptors.",
        "features": "Secondary amine TCA, less anticholinergic than amitriptyline.",
        "clinicalChoice": "Depression, neuropathic pain in elderly.",
        "indications": [
            "Depression",
            "Neuropathic Pain"
        ],
        "contraindications": [
            "Recent MI",
            "MAOIs",
            "Arrhythmias"
        ],
        "sideEffects": [
            "Anticholinergic effects",
            "Sedation",
            "Orthostatic hypotension",
            "QT prolongation",
            "Seizures"
        ],
        "interactions": "MAOIs, QT-prolonging drugs.",
        "interactionDetails": "MAOIS: MECHANISM - Combined serotonin and norepinephrine effects. CONSEQUENCE - Risk of serotonin syndrome and hypertensive crisis. QT PROLONGATION: TCAs have quinidine-like effects, can cause fatal arrhythmias in overdose.",
        "pageType": "drug"
    },
    {
        "id": "bupropion",
        "name": "Bupropion",
        "pharmacologicClass": "atypical-antidepressants",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Dopamine and norepinephrine reuptake inhibitor.",
        "features": "No sexual dysfunction, lowers seizure threshold, used for smoking cessation.",
        "clinicalChoice": "Depression without sexual side effects, smoking cessation.",
        "indications": [
            "Depression",
            "Smoking Cessation",
            "ADHD"
        ],
        "contraindications": [
            "Seizure Disorder",
            "Eating Disorders",
            "MAOIs"
        ],
        "sideEffects": [
            "Seizures",
            "Insomnia",
            "Agitation",
            "Weight loss"
        ],
        "interactions": "CYP2D6 inhibition, lowers seizure threshold.",
        "interactionDetails": "SEIZURE RISK: MECHANISM - Bupropion lowers seizure threshold in dose-dependent manner. CONSEQUENCE - Contraindicated in eating disorders, seizure history, or conditions that lower seizure threshold.",
        "pageType": "drug"
    },
    {
        "id": "mirtazapine",
        "name": "Mirtazapine",
        "pharmacologicClass": "atypical-antidepressants",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Alpha-2 antagonist, increases norepinephrine and serotonin release; also blocks 5-HT2 and 5-HT3 receptors.",
        "features": "Tetracyclic, increases appetite and sedating.",
        "clinicalChoice": "Depression with insomnia and weight loss.",
        "indications": [
            "Depression",
            "Insomnia"
        ],
        "contraindications": [
            "MAOIs"
        ],
        "sideEffects": [
            "Weight gain",
            "Sedation",
            "Increased appetite"
        ],
        "interactions": "MAOIs (serotonin syndrome).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "phenelzine",
        "name": "Phenelzine",
        "pharmacologicClass": "monoamine-oxidase-inhibitors-maois",
        "therapeuticClass": "antidepressants",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Irreversibly inhibit MAO-A and MAO-B, increasing all monoamines.",
        "features": "Requires dietary tyramine restriction to avoid hypertensive crisis.",
        "clinicalChoice": "Atypical depression, social phobia refractory to other treatments.",
        "indications": [
            "Atypical Depression",
            "Social Phobia"
        ],
        "contraindications": [
            "SSRIs/SNRIs/TCAs",
            "Sympathomimetics",
            "Tyramine-Rich Foods"
        ],
        "sideEffects": [
            "Hypertensive crisis (tyramine)",
            "Orthostatic hypotension",
            "Serotonin syndrome"
        ],
        "interactions": "Serotonergic drugs, sympathomimetics, tyramine.",
        "interactionDetails": "TYRAMINE: MECHANISM - MAOIs prevent breakdown of tyramine. Dietary tyramine (cheese, wine, aged meats) acts as indirect sympathomimetic. CONSEQUENCE - Hypertensive crisis with severe headache, stroke risk. SEROTONERGIC DRUGS: Risk of serotonin syndrome, requires 2-week washout.",
        "pageType": "drug"
    },
    {
        "id": "haloperidol",
        "name": "Haloperidol",
        "pharmacologicClass": "typical-antipsychotics",
        "therapeuticClass": "antipsychotics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block D2 dopamine receptors in mesolimbic pathway.",
        "features": "High-potency typical antipsychotic, high EPS risk.",
        "clinicalChoice": "Acute psychosis, delirium, Tourette syndrome.",
        "indications": [
            "Schizophrenia",
            "Acute Psychosis",
            "Delirium",
            "Tourette Syndrome"
        ],
        "contraindications": [
            "Parkinson Disease",
            "Severe CNS Depression"
        ],
        "sideEffects": [
            "Extrapyramidal symptoms",
            "Tardive dyskinesia",
            "Neuroleptic malignant syndrome",
            "QT prolongation"
        ],
        "interactions": "QT-prolonging drugs, anticholinergics.",
        "interactionDetails": "EPS: MECHANISM - D2 blockade in nigrostriatal pathway causes extrapyramidal symptoms. CONSEQUENCE - Acute dystonia, akathisia, parkinsonism. NMS: Rare but life-threatening with fever, rigidity, autonomic instability.",
        "pageType": "drug"
    },
    {
        "id": "chlorpromazine",
        "name": "Chlorpromazine",
        "pharmacologicClass": "typical-antipsychotics",
        "therapeuticClass": "antipsychotics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block D2 dopamine receptors in mesolimbic pathway.",
        "features": "Low-potency typical antipsychotic, more sedating, less EPS.",
        "clinicalChoice": "Schizophrenia, severe nausea.",
        "indications": [
            "Schizophrenia",
            "Bipolar Mania",
            "Severe Nausea"
        ],
        "contraindications": [
            "Severe CNS Depression",
            "Bone Marrow Suppression"
        ],
        "sideEffects": [
            "Extrapyramidal symptoms",
            "Tardive dyskinesia",
            "Neuroleptic malignant syndrome",
            "QT prolongation",
            "Anticholinergic effects",
            "Photosensitivity"
        ],
        "interactions": "QT-prolonging drugs, anticholinergics.",
        "interactionDetails": "EPS: MECHANISM - D2 blockade in nigrostriatal pathway causes extrapyramidal symptoms. CONSEQUENCE - Acute dystonia, akathisia, parkinsonism. NMS: Rare but life-threatening with fever, rigidity, autonomic instability.",
        "pageType": "drug"
    },
    {
        "id": "risperidone",
        "name": "Risperidone",
        "pharmacologicClass": "atypical-antipsychotics",
        "therapeuticClass": "antipsychotics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block D2 and 5-HT2A receptors; serotonin antagonism reduces EPS risk.",
        "features": "First atypical antipsychotic, still has EPS at high doses.",
        "clinicalChoice": "Schizophrenia, bipolar mania, autism irritability.",
        "indications": [
            "Schizophrenia",
            "Bipolar Mania",
            "Autism Irritability"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Weight gain",
            "Metabolic syndrome",
            "Hyperprolactinemia",
            "QT prolongation"
        ],
        "interactions": "CYP2D6 substrates.",
        "interactionDetails": "METABOLIC SYNDROME: MECHANISM - 5-HT2C antagonism and histamine H1 blockade. CONSEQUENCE - Weight gain, diabetes, dyslipidemia. Monitor BMI and metabolic panel.",
        "pageType": "drug"
    },
    {
        "id": "olanzapine",
        "name": "Olanzapine",
        "pharmacologicClass": "atypical-antipsychotics",
        "therapeuticClass": "antipsychotics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block D2 and 5-HT2A receptors; serotonin antagonism reduces EPS risk.",
        "features": "Highest weight gain and metabolic risk among atypicals.",
        "clinicalChoice": "Schizophrenia, bipolar disorder.",
        "indications": [
            "Schizophrenia",
            "Bipolar Disorder"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Weight gain",
            "Metabolic syndrome",
            "Hyperprolactinemia",
            "QT prolongation",
            "Sedation"
        ],
        "interactions": "CYP1A2 substrates.",
        "interactionDetails": "METABOLIC SYNDROME: MECHANISM - 5-HT2C antagonism and histamine H1 blockade. CONSEQUENCE - Weight gain, diabetes, dyslipidemia. Monitor BMI and metabolic panel.",
        "pageType": "drug"
    },
    {
        "id": "quetiapine",
        "name": "Quetiapine",
        "pharmacologicClass": "atypical-antipsychotics",
        "therapeuticClass": "antipsychotics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block D2 and 5-HT2A receptors; serotonin antagonism reduces EPS risk.",
        "features": "Low EPS risk, sedating, used for bipolar depression.",
        "clinicalChoice": "Schizophrenia, bipolar depression.",
        "indications": [
            "Schizophrenia",
            "Bipolar Depression",
            "Bipolar Mania"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Weight gain",
            "Metabolic syndrome",
            "Sedation",
            "Orthostatic hypotension"
        ],
        "interactions": "CYP3A4 substrates.",
        "interactionDetails": "METABOLIC SYNDROME: MECHANISM - 5-HT2C antagonism and histamine H1 blockade. CONSEQUENCE - Weight gain, diabetes, dyslipidemia. Monitor BMI and metabolic panel.",
        "pageType": "drug"
    },
    {
        "id": "aripiprazole",
        "name": "Aripiprazole",
        "pharmacologicClass": "atypical-antipsychotics",
        "therapeuticClass": "antipsychotics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Partial D2 agonist and 5-HT2A antagonist.",
        "features": "Partial D2 agonist, lower metabolic effects, akathisia risk.",
        "clinicalChoice": "Schizophrenia with lower metabolic risk.",
        "indications": [
            "Schizophrenia",
            "Bipolar Disorder",
            "Autism Irritability"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Akathisia",
            "Weight gain (less than others)",
            "Metabolic syndrome (lower risk)"
        ],
        "interactions": "CYP2D6 and CYP3A4 substrates.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "clozapine",
        "name": "Clozapine",
        "pharmacologicClass": "atypical-antipsychotics",
        "therapeuticClass": "antipsychotics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block D2 and 5-HT2A receptors; serotonin antagonism reduces EPS risk.",
        "features": "Treatment-resistant schizophrenia, agranulocytosis risk requires weekly monitoring.",
        "clinicalChoice": "Treatment-resistant schizophrenia.",
        "indications": [
            "Treatment-Resistant Schizophrenia"
        ],
        "contraindications": [
            "Bone Marrow Disorders",
            "Uncontrolled Seizures"
        ],
        "sideEffects": [
            "Agranulocytosis",
            "Seizures",
            "Myocarditis",
            "Weight gain",
            "Metabolic syndrome"
        ],
        "interactions": "Requires weekly WBC monitoring, CYP1A2 substrates.",
        "interactionDetails": "AGRANULOCYTOSIS: MECHANISM - Immune-mediated bone marrow suppression. CONSEQUENCE - Life-threatening infection risk. Requires weekly CBC monitoring for 6 months, then biweekly. Discontinue if WBC <3000 or ANC <1500.",
        "pageType": "drug"
    },
    {
        "id": "lorazepam",
        "name": "Lorazepam",
        "pharmacologicClass": "benzodiazepines",
        "therapeuticClass": "anxiolytics-sedatives",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Enhance GABA-A receptor function, increase chloride influx.",
        "features": "Intermediate-acting, no active metabolites, IM/IV available.",
        "clinicalChoice": "Acute anxiety, status epilepticus, alcohol withdrawal.",
        "indications": [
            "Anxiety",
            "Status Epilepticus",
            "Alcohol Withdrawal"
        ],
        "contraindications": [
            "Acute Narrow-Angle Glaucoma",
            "Severe Respiratory Depression"
        ],
        "sideEffects": [
            "Sedation",
            "Dependence",
            "Respiratory depression",
            "Cognitive impairment"
        ],
        "interactions": "CNS depressants (additive sedation), alcohol.",
        "interactionDetails": "CNS DEPRESSANTS/ALCOHOL: MECHANISM - Additive GABAergic effects. CONSEQUENCE - Profound sedation, respiratory depression, risk of death in overdose. Black box warning for combination with opioids.",
        "pageType": "drug"
    },
    {
        "id": "diazepam",
        "name": "Diazepam",
        "pharmacologicClass": "benzodiazepines",
        "therapeuticClass": "anxiolytics-sedatives",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Enhance GABA-A receptor function, increase chloride influx.",
        "features": "Long-acting, active metabolites, muscle relaxant.",
        "clinicalChoice": "Alcohol withdrawal, muscle spasms, seizures.",
        "indications": [
            "Anxiety",
            "Alcohol Withdrawal",
            "Muscle Spasms",
            "Seizures"
        ],
        "contraindications": [
            "Acute Narrow-Angle Glaucoma",
            "Severe Respiratory Depression"
        ],
        "sideEffects": [
            "Sedation",
            "Dependence",
            "Respiratory depression",
            "Cognitive impairment"
        ],
        "interactions": "CNS depressants (additive sedation), alcohol.",
        "interactionDetails": "CNS DEPRESSANTS/ALCOHOL: MECHANISM - Additive GABAergic effects. CONSEQUENCE - Profound sedation, respiratory depression, risk of death in overdose. Black box warning for combination with opioids.",
        "pageType": "drug"
    },
    {
        "id": "alprazolam",
        "name": "Alprazolam",
        "pharmacologicClass": "benzodiazepines",
        "therapeuticClass": "anxiolytics-sedatives",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Enhance GABA-A receptor function, increase chloride influx.",
        "features": "Short-acting, high abuse potential, severe withdrawal.",
        "clinicalChoice": "Panic disorder, generalized anxiety disorder.",
        "indications": [
            "Panic Disorder",
            "Generalized Anxiety Disorder"
        ],
        "contraindications": [
            "Acute Narrow-Angle Glaucoma",
            "Severe Respiratory Depression"
        ],
        "sideEffects": [
            "Sedation",
            "Dependence",
            "Respiratory depression",
            "Cognitive impairment"
        ],
        "interactions": "CNS depressants (additive sedation), CYP3A4 inhibitors.",
        "interactionDetails": "CNS DEPRESSANTS/ALCOHOL: MECHANISM - Additive GABAergic effects. CONSEQUENCE - Profound sedation, respiratory depression, risk of death in overdose. Black box warning for combination with opioids.",
        "pageType": "drug"
    },
    {
        "id": "clonazepam",
        "name": "Clonazepam",
        "pharmacologicClass": "benzodiazepines",
        "therapeuticClass": "anxiolytics-sedatives",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Enhance GABA-A receptor function, increase chloride influx.",
        "features": "Long-acting, used for seizures and panic disorder.",
        "clinicalChoice": "Panic disorder, seizures, REM sleep behavior disorder.",
        "indications": [
            "Panic Disorder",
            "Seizures",
            "REM Sleep Behavior Disorder"
        ],
        "contraindications": [
            "Acute Narrow-Angle Glaucoma",
            "Severe Respiratory Depression"
        ],
        "sideEffects": [
            "Sedation",
            "Dependence",
            "Respiratory depression",
            "Cognitive impairment"
        ],
        "interactions": "CNS depressants (additive sedation), alcohol.",
        "interactionDetails": "CNS DEPRESSANTS/ALCOHOL: MECHANISM - Additive GABAergic effects. CONSEQUENCE - Profound sedation, respiratory depression, risk of death in overdose. Black box warning for combination with opioids.",
        "pageType": "drug"
    },
    {
        "id": "valproic-acid",
        "name": "Valproic Acid",
        "pharmacologicClass": "mood-stabilizers",
        "therapeuticClass": "mood-stabilizers",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Multiple: increase GABA, block voltage-gated sodium channels, inhibit histone deacetylase.",
        "features": "Broad-spectrum mood stabilizer and antiepileptic.",
        "clinicalChoice": "Bipolar disorder, seizures, migraine prophylaxis.",
        "indications": [
            "Bipolar Disorder",
            "Seizures",
            "Migraine Prophylaxis"
        ],
        "contraindications": [
            "Pregnancy",
            "Liver Disease",
            "Urea Cycle Disorders"
        ],
        "sideEffects": [
            "Hepatotoxicity",
            "Pancreatitis",
            "Neural tube defects",
            "Weight gain",
            "Tremor",
            "Alopecia"
        ],
        "interactions": "Lamotrigine (increases lamotrigine levels), aspirin.",
        "interactionDetails": "LAMOTRIGINE: MECHANISM - Valproate inhibits lamotrigine metabolism. CONSEQUENCE - Doubles lamotrigine levels, increasing Stevens-Johnson syndrome risk. Reduce lamotrigine dose by 50%. PREGNANCY: Major teratogen causing neural tube defects and cognitive impairment.",
        "pageType": "drug"
    },
    {
        "id": "carbamazepine",
        "name": "Carbamazepine",
        "pharmacologicClass": "mood-stabilizers",
        "therapeuticClass": "mood-stabilizers",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block voltage-gated sodium channels.",
        "features": "Strong CYP450 inducer, causes hyponatremia.",
        "clinicalChoice": "Bipolar disorder, trigeminal neuralgia, partial seizures.",
        "indications": [
            "Bipolar Disorder",
            "Trigeminal Neuralgia",
            "Partial Seizures"
        ],
        "contraindications": [
            "Bone Marrow Suppression",
            "MAOIs"
        ],
        "sideEffects": [
            "Hyponatremia (SIADH)",
            "Agranulocytosis",
            "Aplastic anemia",
            "Stevens-Johnson syndrome",
            "Hepatotoxicity"
        ],
        "interactions": "CYP450 inducer (reduces levels of many drugs).",
        "interactionDetails": "CYP INDUCTION: MECHANISM - Carbamazepine induces CYP3A4, CYP2C9. CONSEQUENCE - Reduces levels of oral contraceptives, warfarin, many psychiatric drugs. Also induces own metabolism (autoinduction). HLA-B*1502: Asian patients at high risk for Stevens-Johnson syndrome, screen before starting.",
        "pageType": "drug"
    },
    {
        "id": "lamotrigine",
        "name": "Lamotrigine",
        "pharmacologicClass": "mood-stabilizers",
        "therapeuticClass": "mood-stabilizers",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block voltage-gated sodium channels, inhibit glutamate release.",
        "features": "Best for bipolar depression, Stevens-Johnson syndrome risk with rapid titration.",
        "clinicalChoice": "Bipolar depression, partial seizures.",
        "indications": [
            "Bipolar Depression",
            "Partial Seizures"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Stevens-Johnson syndrome",
            "Rash",
            "Headache",
            "Dizziness"
        ],
        "interactions": "Valproate (doubles lamotrigine levels), oral contraceptives (reduce lamotrigine levels).",
        "interactionDetails": "STEVENS-JOHNSON SYNDROME: MECHANISM - Immune-mediated severe cutaneous reaction. CONSEQUENCE - Life-threatening skin sloughing. Risk increased by rapid titration, valproate co-administration. Titrate slowly, discontinue at first sign of rash.",
        "pageType": "drug"
    },
    {
        "id": "phenytoin",
        "name": "Phenytoin",
        "pharmacologicClass": "sodium-channel-blockers",
        "therapeuticClass": "comprehensive-antiepileptics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block voltage-gated sodium channels to prevent seizure spread.",
        "features": "Zero-order kinetics, many drug interactions, gingival hyperplasia.",
        "clinicalChoice": "Tonic-clonic seizures, status epilepticus.",
        "indications": [
            "Tonic-Clonic Seizures",
            "Status Epilepticus",
            "Partial Seizures"
        ],
        "contraindications": [
            "Sinus Bradycardia",
            "Heart Block"
        ],
        "sideEffects": [
            "Gingival hyperplasia",
            "Hirsutism",
            "Ataxia",
            "Nystagmus",
            "Stevens-Johnson syndrome",
            "Teratogenic (fetal hydantoin syndrome)"
        ],
        "interactions": "Strong CYP450 inducer, zero-order kinetics.",
        "interactionDetails": "ZERO-ORDER KINETICS: MECHANISM - At therapeutic levels, metabolism enzymes are saturated. CONSEQUENCE - Small dose increases cause large serum level increases. Risk of toxicity. CYP INDUCTION: Reduces levels of many drugs including oral contraceptives, warfarin.",
        "pageType": "drug"
    },
    {
        "id": "levetiracetam",
        "name": "Levetiracetam",
        "pharmacologicClass": "other-antiepileptics",
        "therapeuticClass": "comprehensive-antiepileptics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Bind SV2A protein in synaptic vesicles, modulate neurotransmitter release.",
        "features": "Broad spectrum, minimal drug interactions, renally excreted.",
        "clinicalChoice": "Partial seizures, generalized seizures, status epilepticus.",
        "indications": [
            "Partial Seizures",
            "Generalized Seizures",
            "Status Epilepticus"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Behavioral changes",
            "Irritability",
            "Somnolence"
        ],
        "interactions": "Minimal drug interactions.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "topiramate",
        "name": "Topiramate",
        "pharmacologicClass": "other-antiepileptics",
        "therapeuticClass": "comprehensive-antiepileptics",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Multiple: block sodium channels, enhance GABA, antagonize glutamate.",
        "features": "Weight loss, cognitive slowing, kidney stones.",
        "clinicalChoice": "Seizures, migraine prophylaxis.",
        "indications": [
            "Seizures",
            "Migraine Prophylaxis"
        ],
        "contraindications": [
            "Metabolic Acidosis"
        ],
        "sideEffects": [
            "Cognitive slowing",
            "Weight loss",
            "Kidney stones",
            "Metabolic acidosis",
            "Paresthesias"
        ],
        "interactions": "Reduces oral contraceptive efficacy.",
        "interactionDetails": "COGNITIVE EFFECTS: MECHANISM - Multiple CNS effects including carbonic anhydrase inhibition. CONSEQUENCE - Word-finding difficulty, memory problems ('Dopamax'). KIDNEY STONES: Carbonic anhydrase inhibition causes metabolic acidosis and stone formation.",
        "pageType": "drug"
    },
    {
        "id": "donepezil",
        "name": "Donepezil",
        "pharmacologicClass": "acetylcholinesterase-inhibitors",
        "therapeuticClass": "dementia-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Inhibit acetylcholinesterase to increase synaptic acetylcholine.",
        "features": "Most commonly used for Alzheimer's, once-daily dosing.",
        "clinicalChoice": "Mild to moderate Alzheimer's disease.",
        "indications": [
            "Alzheimer Disease"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Nausea",
            "Diarrhea",
            "Bradycardia",
            "Insomnia"
        ],
        "interactions": "Anticholinergics antagonize effects.",
        "interactionDetails": "CHOLINERGIC EFFECTS: MECHANISM - Increased acetylcholine throughout body. CONSEQUENCE - GI upset, bradycardia, urinary frequency. Use caution in cardiac conduction disorders.",
        "pageType": "drug"
    },
    {
        "id": "rivastigmine",
        "name": "Rivastigmine",
        "pharmacologicClass": "acetylcholinesterase-inhibitors",
        "therapeuticClass": "dementia-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Inhibit acetylcholinesterase to increase synaptic acetylcholine.",
        "features": "Also inhibits butyrylcholinesterase, patch formulation available.",
        "clinicalChoice": "Alzheimer's disease, Parkinson's dementia.",
        "indications": [
            "Alzheimer Disease",
            "Parkinson Dementia"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Nausea",
            "Diarrhea",
            "Bradycardia",
            "Insomnia"
        ],
        "interactions": "Anticholinergics antagonize effects.",
        "interactionDetails": "CHOLINERGIC EFFECTS: MECHANISM - Increased acetylcholine throughout body. CONSEQUENCE - GI upset, bradycardia, urinary frequency. Use caution in cardiac conduction disorders.",
        "pageType": "drug"
    },
    {
        "id": "memantine",
        "name": "Memantine",
        "pharmacologicClass": "nmda-antagonists",
        "therapeuticClass": "dementia-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "NMDA receptor antagonist, reduces excitotoxicity.",
        "features": "Different mechanism from cholinesterase inhibitors, can be combined.",
        "clinicalChoice": "Moderate to severe Alzheimer's disease.",
        "indications": [
            "Moderate to Severe Alzheimer Disease"
        ],
        "contraindications": [
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "Dizziness",
            "Confusion",
            "Headache"
        ],
        "interactions": "Minimal drug interactions.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "methylphenidate",
        "name": "Methylphenidate",
        "pharmacologicClass": "stimulants",
        "therapeuticClass": "adhd-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Block dopamine and norepinephrine reuptake in prefrontal cortex.",
        "features": "First-line ADHD treatment, various formulations (short to long-acting).",
        "clinicalChoice": "ADHD, narcolepsy.",
        "indications": [
            "ADHD",
            "Narcolepsy"
        ],
        "contraindications": [
            "MAOIs",
            "Glaucoma",
            "Severe Anxiety"
        ],
        "sideEffects": [
            "Insomnia",
            "Decreased appetite",
            "Growth suppression",
            "Tachycardia",
            "Hypertension"
        ],
        "interactions": "MAOIs (hypertensive crisis).",
        "interactionDetails": "CARDIAC EFFECTS: MECHANISM - Increased catecholamines. CONSEQUENCE - Tachycardia, hypertension. Screen for cardiac disease before starting. GROWTH SUPPRESSION: Monitor height/weight in children, consider drug holidays.",
        "pageType": "drug"
    },
    {
        "id": "amphetamine-dextroamphetamine",
        "name": "Amphetamine/Dextroamphetamine",
        "pharmacologicClass": "stimulants",
        "therapeuticClass": "adhd-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Increase dopamine and norepinephrine release and block reuptake.",
        "features": "Mixed amphetamine salts (Adderall), high abuse potential.",
        "clinicalChoice": "ADHD, narcolepsy.",
        "indications": [
            "ADHD",
            "Narcolepsy"
        ],
        "contraindications": [
            "MAOIs",
            "Hyperthyroidism",
            "Severe Cardiovascular Disease"
        ],
        "sideEffects": [
            "Insomnia",
            "Decreased appetite",
            "Growth suppression",
            "Tachycardia",
            "Hypertension"
        ],
        "interactions": "MAOIs (hypertensive crisis).",
        "interactionDetails": "CARDIAC EFFECTS: MECHANISM - Increased catecholamines. CONSEQUENCE - Tachycardia, hypertension. Screen for cardiac disease before starting. GROWTH SUPPRESSION: Monitor height/weight in children, consider drug holidays.",
        "pageType": "drug"
    },
    {
        "id": "atomoxetine",
        "name": "Atomoxetine",
        "pharmacologicClass": "non-stimulant-adhd-medications",
        "therapeuticClass": "adhd-medications",
        "system": "psychiatry-neurology-expanded",
        "mechanism": "Selective norepinephrine reuptake inhibitor.",
        "features": "Non-stimulant ADHD treatment, lower abuse potential.",
        "clinicalChoice": "ADHD when stimulants contraindicated or ineffective.",
        "indications": [
            "ADHD"
        ],
        "contraindications": [
            "MAOIs",
            "Narrow-Angle Glaucoma"
        ],
        "sideEffects": [
            "Decreased appetite",
            "Nausea",
            "Insomnia",
            "Suicidal ideation (black box warning)"
        ],
        "interactions": "CYP2D6 substrates.",
        "interactionDetails": "SUICIDAL IDEATION: MECHANISM - Unknown. CONSEQUENCE - Black box warning for increased suicidal thoughts in children/adolescents. Monitor closely especially early in treatment.",
        "pageType": "drug"
    }

];export default drugs;
